MX2011010616A - Metodos para tratar edema relacionado a isquemia-reperfusion. - Google Patents

Metodos para tratar edema relacionado a isquemia-reperfusion.

Info

Publication number
MX2011010616A
MX2011010616A MX2011010616A MX2011010616A MX2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A
Authority
MX
Mexico
Prior art keywords
reperfusion
ischemia
methods
treating edema
edema related
Prior art date
Application number
MX2011010616A
Other languages
English (en)
Inventor
Thomas Michael Egan
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of MX2011010616A publication Critical patent/MX2011010616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen métodos para prevenir o reducir edema relacionado a isquemia-reperfusión al tratar el árgano o tejido que se trasplanta con un fosfato de aminoalquil-glucosaminida.
MX2011010616A 2009-04-09 2010-04-09 Metodos para tratar edema relacionado a isquemia-reperfusion. MX2011010616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (1)

Publication Number Publication Date
MX2011010616A true MX2011010616A (es) 2012-03-14

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010616A MX2011010616A (es) 2009-04-09 2010-04-09 Metodos para tratar edema relacionado a isquemia-reperfusion.

Country Status (14)

Country Link
US (1) US20120064044A1 (es)
EP (1) EP2416651A4 (es)
JP (1) JP2012523432A (es)
KR (1) KR20120005025A (es)
CN (1) CN102458113A (es)
AU (1) AU2010233151A1 (es)
BR (1) BRPI1010516A2 (es)
CA (1) CA2757998A1 (es)
EA (1) EA201101349A1 (es)
IL (1) IL215604A0 (es)
MX (1) MX2011010616A (es)
SG (1) SG175133A1 (es)
WO (1) WO2010118334A1 (es)
ZA (1) ZA201107815B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009234156A1 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
CA2828002A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP7330893B2 (ja) 2017-03-10 2023-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11458151B2 (en) 2018-02-12 2022-10-04 Inimmune Corporation Toll-like receptor ligands
JP2021528421A (ja) 2018-06-20 2021-10-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 細胞保護の方法と組成物
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトａｄｆを含有する臓器保護剤
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
EP2170366B1 (en) * 2007-08-03 2013-11-06 Opsona Therapeutics Limited Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
AU2009234156A1 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Also Published As

Publication number Publication date
SG175133A1 (en) 2011-12-29
CN102458113A (zh) 2012-05-16
EP2416651A1 (en) 2012-02-15
CA2757998A1 (en) 2010-10-14
US20120064044A1 (en) 2012-03-15
BRPI1010516A2 (pt) 2015-08-25
ZA201107815B (en) 2013-04-24
AU2010233151A1 (en) 2011-11-17
KR20120005025A (ko) 2012-01-13
EA201101349A1 (ru) 2012-05-30
WO2010118334A1 (en) 2010-10-14
IL215604A0 (en) 2011-12-29
JP2012523432A (ja) 2012-10-04
EP2416651A4 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2011010616A (es) Metodos para tratar edema relacionado a isquemia-reperfusion.
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX343363B (es) Metodos para recelularizar un tejido o un organo para una transplantabilidad mejorada.
MX366955B (es) Crlx101 para usarse en el tratamiento de cáncer.
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
EP2558582A4 (en) MICROORGANISMS AND PROCESSES FOR THE PRODUCTION OF ETHYLENE GLYCOL
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
MX2011006290A (es) Compuestos de aza-azuleno.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
IN2014DN11201A (es)
GB2497475A (en) Kits, components and methods for tissue reconstruction
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
MX2015003701A (es) Composiciones para tratamiento.
MX337486B (es) Fibras de degradacion controlada.
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
MY160127A (en) Method for treatment of diseases
WO2010083215A3 (en) Composition and method for the treatment of diseases affected by apoptosis
IN2012DN03404A (es)
HK1124842A1 (en) Methods of preparing imidazole-based compounds
IN2012DN02760A (es)
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal